Therefore, LINC01132 promotes HCC development through the NRF1/DPP4 axis, and targeting LINC01132 may enhance the efficacy of anti-PD-L1 immunotherapy (56). The gene discussed is DPP4; the disease is hepatocellular carcinoma.